HYCAMTIN Drug Patent Profile

Which patents cover Hycamtin, and when can generic versions of Hycamtin launch?

Hycamtin is a drug marketed by Sandoz and is included in two NDAs.

The generic ingredient in HYCAMTIN is topotecan hydrochloride. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hycamtin

A generic version of HYCAMTIN was approved as topotecan hydrochloride by FRESENIUS KABI USA on November 29^th, 2010.

Summary for HYCAMTIN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	118
Patent Applications:	6,391
Drug Prices:	Drug price information for HYCAMTIN
What excipients (inactive ingredients) are in HYCAMTIN?	HYCAMTIN excipients list
DailyMed Link:	HYCAMTIN at DailyMed

See drug prices for HYCAMTIN

Recent Clinical Trials for HYCAMTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GOG Foundation	Phase 3
European Network of Gynaecological Oncological Trial Groups (ENGOT)	Phase 3
Verastem, Inc.	Phase 3

See all HYCAMTIN clinical trials

Pharmacology for HYCAMTIN

Drug Class	Topoisomerase Inhibitor
Mechanism of Action	Topoisomerase Inhibitors

US Patents and Regulatory Information for HYCAMTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-001	Oct 11, 2007		RX	Yes	No
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-002	Oct 11, 2007		RX	Yes	Yes
Sandoz	HYCAMTIN	topotecan hydrochloride	INJECTABLE;INJECTION	020671-001	May 28, 1996	AP	RX	Yes	Yes

Expired US Patents for HYCAMTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-001	Oct 11, 2007
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-002	Oct 11, 2007

International Patents for HYCAMTIN

See the table below for patents covering HYCAMTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	88517	Water soluble camptothecin analogs, their preparation, pharmaceutical compositions containing them, some intermediates thereof and their preparation
Slovakia	397391	9,10-SUBSTITUTED CAMPTOTHECINS, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND AN INTERMEDIATE
Taiwan	200530250	Novel compound, corresponding compositions, preparation and/or treatment methods
China	1913897	Novel compound, corresponding compositions, preparation and/or treatment methods
Greece	3021990
China	1035380
Canada	2545876	NOUVEAU COMPOSE, COMPOSITIONS CORRESPONDANTES, METHODES DE FABRICATION ET/OU DE TRAITEMENT (NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS)

Supplementary Protection Certificates for HYCAMTIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0321122	SPC/GB96/057	United Kingdom		PRODUCT NAME: TOPOTECAN; REGISTERED: CH IKS-NR:53857 19961016; UK EU/1/96/027/001 19961112; UK EU/1/96/027/002 19961112
0321122	C970017	Netherlands		PRODUCT NAME: TOPOTECAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZOUT, HYDRAAT OF SOLVAAT, IN HET BIJZONDER HET HYDROCHLORI DE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 - EU/1/96/027/002 19961112; FIRST REGISTRATION: CH IKS 53857 19961016
0321122	2/1997	Austria		PRODUCT NAME: TOPOTECAN; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 EU/1/96/027/002 19961112; FIRST REGISTRATION: LI 53857 01 19961016
0321122	97C0009	Belgium		PRODUCT NAME: TOPOTECAN HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 19961112 ; FIRST REGISTRATION: CH 53857 19961016

HYCAMTIN (topotecan): Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

Where does HYCAMTIN sit in the topotecan market?

Hycamtin (topotecan) is an oncology product with a focused label and limited direct therapeutic substitutability within its use cases. The commercial story is shaped by three forces: (1) label scope and line-of-therapy constraints, (2) generic erosion risk typical for small-molecule oncology drugs, and (3) payer and hospital purchasing behavior that drives utilization more than pure clinical positioning.

Market structure that drives demand

• Core demand driver: guideline and payer pathway alignment for topotecan in approved indications rather than broad front-line substitution.
• Utilization channel: oncology infusion centers and hospital formularies where contracting, drug cost, and administration logistics matter.
• Price pressure: intensified by the presence of generic topotecan supply and the standard oncology procurement practice of formulary tiering and switching when pricing gaps are large.

Competitive set (practical substitution)

Hycamtin competes primarily against:

• Generic topotecan products (same active ingredient; competitive on price and supply continuity).
• Alternative oncology regimens within the same disease spaces when clinical pathways permit switching away from topotecan.

What demand levers move Hycamtin’s sales?

Sales trajectory for Hycamtin is linked to a narrow set of levers rather than broad market expansion.

Clinical and labeling levers

• Indication depth, not breadth: Hycamtin’s commercial ceiling depends on where topotecan stays embedded in treatment algorithms.
• Therapy sequencing sensitivity: utilization declines when evidence or practice shifts push topotecan earlier, later, or out of standard second-line and salvage settings.

Commercial and procurement levers

• Formulary access: hospital systems negotiate rebates and conversion terms, typically favoring lower net cost.
• Acquisition behavior: oncology centers often standardize on fewer SKUs to reduce pharmacy complexity; that favors the lowest-cost stable supplier.
• Supply and contracting: drug shortages or contract changes can cause short-term volatility even when underlying patient demand is steady.

How has generic entry influenced the financial path?

Generic topotecan creates a persistent pricing ceiling for the reference brand.

Economic mechanism

• Once generic volume takes hold, brand sales typically shift to:
  • remaining patients covered under less price-sensitive channels, or
  • periods of temporary supply leverage, or
  • contract-specific carve-outs.
• Over longer windows, brand net pricing compresses and promotional spend may not offset margin erosion.

Observable consequence

• For reference brands in small-molecule oncology, the financial pattern usually shows:
  • pre-generic stability, then
  • post-generic decline with sporadic recoveries tied to contracting and availability.

What does the historical financial trajectory indicate?

Hycamtin’s market dynamics align with a late-life oncology product pattern: brand revenue generally declines over time under generic pressure unless a label expansion or procurement advantage changes the math.

Sales trajectory (directional, market-typical)

• Near-term sensitivity: contract cycles and payer formularies can move net sales quarter-to-quarter.
• Long-run trend: downward bias from generic substitution and continued price competition.

Where the financial “shape” comes from

• Oncology is spend-constrained: budgets at large hospital systems enforce annual drug spend caps.
• Small molecule substitution is easy: generic equivalence reduces clinical friction and shifts purchasing decisions to price and supply.

How do payer and hospital policies affect net revenue?

Net sales for oncology drugs are usually more responsive to reimbursement and contracting than to gross list pricing. For Hycamtin, the key policy touchpoints are:

Payer dynamics

• Coverage determinations for second-line and salvage settings often use prior authorization and medical policy language that can steer regimens.
• Site-of-care (hospital outpatient vs infusion centers) influences reimbursement levels and contracting outcomes.

Hospital dynamics

• Group purchasing and GPO leverage drive standardized choices and favor lower-cost generics.
• Formulary maintenance tends to push branded products off formulary tiers when net pricing no longer beats generics after rebate structures.

What are the most material market risks to watch?

Market risk for Hycamtin comes from structural and operational sources.

Structural risks

• Further generic supply expansion can accelerate downward pricing.
• Changes in clinical pathways that shift away from topotecan reduce addressable volume even if generics remain limited.

Operational risks

• Manufacturing or supply continuity affects infusion schedules and can temporarily change utilization shares between products.
• Contracting resets can create short, sharp revenue changes independent of patient numbers.

What does the current commercial outlook imply for value creation?

For investors or business developers, the value thesis for Hycamtin is less about growth and more about risk-adjusted cash flows under ongoing generic pressure.

Most likely value drivers

• Maintaining formulary presence through contracting and reliable supply.
• Minimizing net price erosion via brand-specific agreements where feasible.
• Defending usage within remaining guideline windows where topotecan retains clinical acceptance.

Most likely constraints

• No durable volume growth absent label shifts into broader lines of therapy.
• Margin compression once generic penetration reaches dominant levels.

Financial trajectory: what it means in practice

Hycamtin’s financial trajectory should be evaluated through two separate lenses: net revenue and profitability resilience.

Net revenue reality

• Net sales typically follow:
  • patient demand,
  • generic mix,
  • payer and hospital formulary position,
  • contracting outcomes.

Profitability reality

• Even if unit volumes hold up in narrow settings, brand profitability generally degrades once:
  • rebates must increase to preserve share, or
  • competitive pricing compresses net price.

Key metrics to map the trajectory

Use the following metrics to translate market dynamics into a financial model.

Metric	What it tells you	Why it moves Hycamtin
Generic penetration (by volume)	How much demand shifted	Directly caps brand pricing power
Hospital formulary tier status	Access probability	Drives steady-state utilization
Net price trend vs list	Margin compression pressure	Reflects contracting strength
Patient mix by line of therapy	Demand durability	Topotecan is sequencing-sensitive
Contract cycle timing	Revenue volatility	Explains quarter-to-quarter swings

Key Takeaways

• HYCAMTIN’s market is structurally constrained by label and line-of-therapy placement and by the ease of generic substitution for topotecan.
• Revenue trajectory is dominated by hospital and payer contracting, not by broad market expansion.
• The financial profile most consistent with the market structure is steady utilization in narrow windows paired with ongoing net price and margin pressure as generic penetration persists.
• The most material risks are generic mix acceleration and clinical pathway shifts that move topotecan out of standard sequencing.

FAQs

1. What drives HYCAMTIN sales most?
   Formulary access and contracting within oncology settings where topotecan remains part of recommended sequencing.

2. How does generic competition typically affect a reference oncology brand like HYCAMTIN?
   It compresses net pricing and shifts volume to lower-cost alternatives, lowering brand revenue growth and usually margins.

3. Is HYCAMTIN’s demand primarily growth or defense?
   Defense: demand is maintained only in constrained clinical windows unless labels or practice patterns expand topotecan usage.

4. Why do HYCAMTIN sales show volatility even when patient demand is stable?
   Contract resets, GPO purchasing decisions, and site-of-care reimbursement shifts can change utilization and net revenue quickly.

5. What is the highest-value signal for future trajectory?
   Changes in generic penetration and formulary tier position, since both directly determine net pricing and sustained volume.

References

[1] APA (American Psychological Association). Publication Manual of the American Psychological Association. (7th ed.). American Psychological Association.